| Dr Ingrid Mary Elizabeth De Baintner, MD | |
|
1 Meeting House Hill Rd, Dover, MA 02030-2135 | |
| (508) 785-2455 | |
| Not Available |
| Full Name | Dr Ingrid Mary Elizabeth De Baintner |
|---|---|
| Gender | Female |
| Speciality | Preventive Medicine - Sports Medicine |
| Location | 1 Meeting House Hill Rd, Dover, Massachusetts |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205037140 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083S0010X | Preventive Medicine - Sports Medicine | 46004 (Massachusetts) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ingrid Mary Elizabeth De Baintner, MD 1 Meeting House Hill Rd, Dover, MA 02030-2135 Ph: (508) 785-2455 | Dr Ingrid Mary Elizabeth De Baintner, MD 1 Meeting House Hill Rd, Dover, MA 02030-2135 Ph: (508) 785-2455 |
News Archive
Scientists at The Scripps Research Institute have found the first chemical compounds that act to block an enzyme that has been linked to inflammatory conditions such as asthma and arthritis, as well as some inflammation-promoted cancers.
North Carolina State University chemists have created a compound that makes existing antibiotics 16 times more effective against recently discovered antibiotic-resistant "superbugs."
ADVENTRX Pharmaceuticals, Inc. today announced that it has resolved the stockholders' equity continued listing deficiencies originally identified by the NYSE Amex in a June 2009 letter to the Company. In part to address the NYSE Amex's requirement that the Company address its low stock price, ADVENTRX also announced that its Board of Directors has approved a 1-for-25 reverse split of its common stock, which was authorized by its stockholders at a special meeting held in August 2009.
Halfpenny Technologies, Inc., a leading health information exchange (HIE) company that enables interoperability between physician electronic medical record systems (EMRs) and hospitals, laboratories and other ancillary service providers, today announced that American Pathology Partners, a nationwide, private diagnostic testing services provider based in Nashville, Tenn., will deploy the company's Integration Technology Framework (ITF) platform.
Biogen Idec announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of AVONEX® PEN™ for patients with relapsing multiple sclerosis (MS) and patients with a single demyelinating event.
› Verified 6 days ago